Multiple Sclerosis Drugs - Angola

Angola

The projected revenue for the Multiple Sclerosis Drugs market in Angola is expected to reach US$5.05m in 2024.
It is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 1.09%, leading to a market volume of US$5.33m by 2029.
In global comparison, United States is expected to generate the highest revenue with US$11,770.00m in 2024.
Despite the growing prevalence of Multiple Sclerosis in Angola, access to effective drugs remains limited due to high costs and limited healthcare infrastructure.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Angola has been steadily growing over the past few years.

Customer preferences: Angolan customers prefer drugs that are affordable and effective. They are willing to try new drugs that have been proven to work well in other markets.

Trends in the market: The market for Multiple Sclerosis Drugs in Angola has been growing steadily due to an increase in awareness of the disease and the availability of new drugs. There has been a shift towards the use of more effective drugs that have fewer side effects. The market is expected to continue to grow as more people are diagnosed with Multiple Sclerosis and as new drugs become available.

Local special circumstances: Angola has a high prevalence of Multiple Sclerosis due to a combination of genetic and environmental factors. The disease is more common in women than men. The lack of access to healthcare in remote areas of the country has made it difficult for some patients to receive treatment.

Underlying macroeconomic factors: Angola's economy has been growing rapidly in recent years due to an increase in oil production. This has led to an increase in healthcare spending, which has helped to drive the growth of the Multiple Sclerosis Drugs market. The government has been investing in healthcare infrastructure to improve access to healthcare in remote areas of the country. This has helped to increase the number of patients who are able to receive treatment for Multiple Sclerosis.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.